# Caremo

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/caremo

- Industry: Biotechnology
- Headquarters: Nanjing, China
- Website: www.caremo.com.cn
- Total disclosed funding: $37M
- Latest round: Series B (Aug 26, 2025)
- Investors on record: 4

## About

Based in Nanjing, China, and founded in 2020, Nanjing Kemo Biomedical Co., Ltd operates as a biotenology company that committed to providing drug discovery full life cycle services for biotechnology and pharmaceutical enterprises. As of August 2023, it has more than 400 employees. It has R&D lab with11,000 square meters, and equipped with over 500 devices. It has three branches in Nanjing. In April 2023, Caremo raised CNY 100 million in series A+ funding led by new investor Tsing Song Capital, with participation from returning investor Zhejiang Shapuaisi Pharmaceutical. In August 2025, Caremo raised a series B1 funding from returning investors Jolmo Capital and Coastal Capital. The company's business can be categorized into drug screening, cell biology, pharmacology and efficacy, drug metabolism, non-clinical safety evaluation, formulation technology, clinical research, customizable development and new drug investment. The company generates revenue by researching and providing its own drug products. The company will develop its business and build its R&D platform.

## Funding rounds

- Series B, Aug 26, 2025 — Coastal Capital, Jolmo Capital
- Series A, Apr 28, 2023, $14M — Tsing Song Capital, Zhejiang Shapuaisi Pharmaceutical
- Series A, Jun 18, 2022, $22M — Coastal Capital, Jolmo Capital, Zhejiang Shapuaisi Pharmaceutical

## Investors

- Coastal Capital (https://capitalatlas.ai/funds/coastal-capital) — Series A, Series B
- Jolmo Capital (https://capitalatlas.ai/funds/jolmo-capital) — Series A, Series B
- Zhejiang Shapuaisi Pharmaceutical — Series A
- Tsing Song Capital (https://capitalatlas.ai/funds/tsing-song-capital) — Series A